Welcome to our dedicated page for QIAGEN N.V. news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on QIAGEN N.V. stock.
QIAGEN N.V. (symbol: QGEN) is a leading global provider of sample-to-insight solutions that transform biological materials into valuable molecular insights. The company's sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. Its assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases from QIAGEN interpret data to report relevant, actionable insights. Automation solutions tie these components together in seamless and cost-effective molecular testing workflows.
QIAGEN serves a diverse customer base of over 500,000 worldwide in sectors such as molecular diagnostics (human healthcare), applied testing (forensics, veterinary testing, and food safety), pharma (pharmaceutical and biotechnology companies), and academia (life sciences research). As of June 30, 2015, the company employed approximately 4,400 people across 35 locations globally. Additional information can be found on their website at http://www.qiagen.com.
QIAGEN's proprietary sample and assay technology enables the extraction, purification, amplification, and interpretation of DNA, RNA, and proteins. The company's revenue is almost evenly split between life sciences and molecular diagnostics applications, with nearly 90% of its revenue derived from consumables and the remaining from instrumentation and related services. The largest portion of QIAGEN's revenue comes from the Americas (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
Recent achievements include:
- Q1 2024 net sales of $459 million (-5% at actual rates, -5% at constant exchange rates, CER), with a diluted EPS of $0.36 and an adjusted diluted EPS of $0.46. The net sales at CER of $462 million were ahead of the outlook for at least $455 million CER, and the adjusted diluted EPS of $0.47 CER was ahead of the $0.44 CER outlook.
- Strong operating cash flow rose by 85% to $133 million versus Q1 2023.
- The QCI Secondary Analysis software, integrated with QCI Interpret, facilitates high-throughput secondary analysis of clinical next-generation sequencing data.
- Collaborations aimed at creating novel digital PCR assays to improve DNA analysis in forensics and human identification.
- Introduction of the QIAstat-Dx Respiratory Panel Plus for accurate diagnosis of respiratory infections, capable of generating results in about one hour with minimal hands-on time.
- Enhancements to the QIAGEN Clinical Insight Interpret platform, which has processed over 4 million NGS patient test cases for oncology and hereditary diseases worldwide.
- New QIAcuity digital PCR Custom Assay Design Tool for copy number variation analysis, complementing the company's existing assay offerings.
QIAGEN continues to innovate and maintain its leading position in the molecular diagnostics and life sciences industries. The company's ongoing efforts to expand its product offerings and enhance its technologies ensure that it remains a trusted partner for researchers and healthcare providers worldwide.
QIAGEN has launched its QIAwave nucleic-acid extraction kits, achieving a 35% lower environmental impact compared to standard kits. The products are the first in the industry to receive the ACT Environmental Impact Factor Label from
QIAGEN has launched the QIAstat-Dx Rise, an advanced automated syndromic testing system receiving CE-marking, enabling up to 56 tests in an eight-hour shift. The system enhances the capacity for detecting multiple pathogens simultaneously, crucial for high-demand medical facilities. Key updates include an expanded QIAstat-Dx Respiratory SARS-CoV-2 Panel that now tests for 23 pathogens, including Chlamydophila pneumoniae, and a new Gastrointestinal Panel with improved performance. Additionally, a software update enhances cybersecurity and connectivity for the QIAstat-Dx systems.
QIAGEN has acquired a 96% stake in BLIRT SA, enhancing its capabilities in recombinant enzymes and molecular biology reagents. BLIRT, based in Poland, specializes in producing essential proteins and enzymes for diagnostics, generating under $10 million in sales in 2021. This acquisition aims to bolster QIAGEN's sample technologies business, expand global production, and enhance R&D capacities. The deal is expected to close in Q2 2022 and will not materially impact QIAGEN's financial outlook for the year, as previously stated.
QIAGEN N.V. announced Dr. Eva Pisa as a proposed new member of the Supervisory Board, enhancing leadership in the Life Science and Molecular Diagnostics sectors. All current board members will stand for re-election at the Annual General Meeting scheduled for June 23, 2022, in Venlo, Netherlands. Dr. Pisa's experience includes roles at Sangtec Molecular Diagnostics and Roche Diagnostics, offering valuable insights into health diagnostics. This strategic move aligns with QIAGEN's commitment to value creation for stakeholders in the Life Science and Molecular Diagnostics markets.
QIAGEN has announced the availability of its NeuMoDx HSV 1/2 Quant Assay for detecting herpes simplex virus type 1 and 2, following its CE-IVD certification. This assay enhances QIAGEN's offerings in viral load monitoring, particularly for immunocompromised patients, now totaling 15 CE-IVD assays for the NeuMoDx systems. The new assay is critical for organ transplant patients, addressing significant mortality risks from herpesvirus infections. QIAGEN also plans to launch additional assays in 2022, including tests for HHV-6 and reformulated EBV assays.
QIAGEN N.V. reported a strong Q1 2022, with net sales growing 11% to
QIAGEN N.V. (NYSE: QGEN) announced it will release its first quarter 2022 results on April 27 at 22:05 Frankfurt time. A conference call will follow on April 28 at 16:00 Frankfurt time, hosted by CEO Thierry Bernard and CFO Roland Sackers. Investors can join via phone or access an audio webcast. This call will provide insights into the company's financial performance and strategic developments.
On World TB Day, QIAGEN announced its QuantiFERON blood test has screened over 100 million patients for tuberculosis (TB), solidifying its status as the gold standard in TB testing. This test, utilized in over 130 countries, offers a more accurate alternative to traditional skin tests. With accurate testing, it aims to prevent 1.5 million TB-related deaths annually. QIAGEN is also expanding its QuantiFERON franchise and has introduced a portable version for low-resource settings, further enhancing its impact on TB diagnosis and control.
QIAGEN N.V. (NYSE: QGEN) has filed its annual report, including audited financial statements for the year ended December 31, 2021, with the U.S. Securities and Exchange Commission. Shareholders can request printed copies free of charge. QIAGEN specializes in providing Sample to Insight solutions, serving over 500,000 customers worldwide in fields such as Molecular Diagnostics, Applied Testing, Pharma, and Academia. The company employs over 6,000 staff across 35 locations. For further details, the report is accessible on QIAGEN’s website.
QIAGEN N.V. (NYSE: QGEN) reported a 2% increase in Q4 2021 net sales, reaching $582 million, significantly above the expected decline. The full-year net sales surged 20% to $2.25 billion, with adjusted diluted EPS rising 23% to $2.65. The non-COVID product sales grew by 22% (CER), exceeding the 20% target. QIAGEN anticipates 2022 net sales of at least $2.07 billion, expecting double-digit growth in non-COVID products. Strong cash flow metrics were highlighted, with operating cash flow rising 40% to $639 million and free cash flow up 38% to $449 million.
FAQ
What is the current stock price of QIAGEN N.V. (QGEN)?
What is the market cap of QIAGEN N.V. (QGEN)?
What does QIAGEN N.V. do?
How many employees does QIAGEN N.V. have?
What are QIAGEN's recent financial achievements?
What industries does QIAGEN serve?
What are QIAGEN’s proprietary technologies?
Where can I find more information about QIAGEN?
What are some of QIAGEN's recent innovations?
How is QIAGEN's revenue split?
Which regions contribute most to QIAGEN's revenue?
What is the QIAstat-Dx Respiratory Panel Plus?
